195 related articles for article (PubMed ID: 11571582)
21. Interrogating androgen receptor function in recurrent prostate cancer.
Zhang L; Johnson M; Le KH; Sato M; Ilagan R; Iyer M; Gambhir SS; Wu L; Carey M
Cancer Res; 2003 Aug; 63(15):4552-60. PubMed ID: 12907631
[TBL] [Abstract][Full Text] [Related]
22. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
23. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O
Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
[TBL] [Abstract][Full Text] [Related]
24. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors.
Hsieh CL; Yang L; Miao L; Yeung F; Kao C; Yang H; Zhau HE; Chung LW
Cancer Res; 2002 Jun; 62(11):3084-92. PubMed ID: 12036918
[TBL] [Abstract][Full Text] [Related]
25. Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector.
Wang D; Wang Z; Tian J; He X; Chowdhury WH; Zhang X; Li S; Rodriguez R
Urol Oncol; 2010; 28(2):164-9. PubMed ID: 18440837
[TBL] [Abstract][Full Text] [Related]
26. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells.
Horii K; Suzuki Y; Kondo Y; Akimoto M; Nishimura T; Yamabe Y; Sakaue M; Sano T; Kitagawa T; Himeno S; Imura N; Hara S
Mol Cancer Res; 2007 Apr; 5(4):383-91. PubMed ID: 17426252
[TBL] [Abstract][Full Text] [Related]
27. A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter.
Shi CX; Graham FL; Hitt MM
J Gene Med; 2006 Apr; 8(4):442-51. PubMed ID: 16389604
[TBL] [Abstract][Full Text] [Related]
28. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter.
Cleutjens KB; van der Korput HA; van Eekelen CC; van Rooij HC; Faber PW; Trapman J
Mol Endocrinol; 1997 Feb; 11(2):148-61. PubMed ID: 9013762
[TBL] [Abstract][Full Text] [Related]
29. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.
Gabril MY; Onita T; Ji PG; Sakai H; Chan FL; Koropatnick J; Chin JL; Moussa M; Xuan JW
Gene Ther; 2002 Dec; 9(23):1589-99. PubMed ID: 12424611
[TBL] [Abstract][Full Text] [Related]
30. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.
Rodriguez R; Schuur ER; Lim HY; Henderson GA; Simons JW; Henderson DR
Cancer Res; 1997 Jul; 57(13):2559-63. PubMed ID: 9205053
[TBL] [Abstract][Full Text] [Related]
31. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging.
Adams JY; Johnson M; Sato M; Berger F; Gambhir SS; Carey M; Iruela-Arispe ML; Wu L
Nat Med; 2002 Aug; 8(8):891-7. PubMed ID: 12134144
[TBL] [Abstract][Full Text] [Related]
32. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter.
Xie X; Zhao X; Liu Y; Young CY; Tindall DJ; Slawin KM; Spencer DM
Hum Gene Ther; 2001 Mar; 12(5):549-61. PubMed ID: 11268287
[TBL] [Abstract][Full Text] [Related]
33. Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival.
Zhang L; Brereton HM; Hahn M; Froscio M; Tilley WD; Brown MP; Barritt GJ
Cancer Gene Ther; 2003 Aug; 10(8):611-25. PubMed ID: 12872143
[TBL] [Abstract][Full Text] [Related]
34. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility.
Lai J; Kedda MA; Hinze K; Smith RL; Yaxley J; Spurdle AB; Morris CP; Harris J; Clements JA
Carcinogenesis; 2007 May; 28(5):1032-9. PubMed ID: 17151093
[TBL] [Abstract][Full Text] [Related]
35. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
36. In vivo sodium iodide symporter gene therapy of prostate cancer.
Spitzweg C; Dietz AB; O'Connor MK; Bergert ER; Tindall DJ; Young CY; Morris JC
Gene Ther; 2001 Oct; 8(20):1524-31. PubMed ID: 11704812
[TBL] [Abstract][Full Text] [Related]
37. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
38. CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression.
Liu BH; Wang X; Ma YX; Wang S
Gene Ther; 2004 Jan; 11(1):52-60. PubMed ID: 14681697
[TBL] [Abstract][Full Text] [Related]
39. Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors.
Shi CX; Hitt M; Ng P; Graham FL
Hum Gene Ther; 2002 Jan; 13(2):211-24. PubMed ID: 11812278
[TBL] [Abstract][Full Text] [Related]
40. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.
Yu DC; Chen Y; Seng M; Dilley J; Henderson DR
Cancer Res; 1999 Sep; 59(17):4200-3. PubMed ID: 10485454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
